title: [Intellectual property, patents and access to medication in developing countries].
abstract: Pharmaceutical industry depends on continuing research and innovation to survive. This is a highly uncertain process due to the fact that only one in 20,000 screened molecules becomes a new and effective medicine. This process takes about 10 years to complete at a cost of e 480,000 per new compound. It is absolutely mandatory that intellectual property rights be protected in order to allow for investment of revenues in research and development of new medicines destined to cure or alleviate all types of disease, including those mainly afflicting the population in developing countries. The investigative drive of pharmaceutical companies has given the sector a leadership role in the search for global health. This is a responsibility the sector acknowledges and for that reason numerous laboratories are active partners of governments, private foundations, international organizations and N.G.O.s in a myriad of initiatives focused on alleviating most urgent health needs in developing countries. However, the true and final solution of this problem will only be accomplished when the social and political issues plagueing these societies are tackled.
authors.affiliation: Farmaindustria. Departamento técnico, Madrid, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Esteve
mesh_terms: D003906:Developing Countries; D004345:Drug Industry; D006297:Health Services Accessibility; D006801:Humans; D018973:Intellectual Property; D010330:Patents as Topic; D004364:Pharmaceutical Preparations; D012106:Research
chemical_list: D004364:Pharmaceutical Preparations